Effects of the sibutramine therapy on pulmonary artery pressure in obese patients

Guven A., Koksal N., Cetinkaya A., Sokmen G., Ozdemir R.

DIABETES OBESITY & METABOLISM, vol.6, no.1, pp.50-55, 2004 (SCI-Expanded) identifier identifier identifier


Aim: Obesity is a major global public health problem. Previous drugs (dexfenfluramine and fenfluramine) used for the treatment of obesity have been withdrawn due to various cardiac side effects. Sibutramine is an anti-obesity agent. The purpose of this study was to assess cardiac valve disease and pulmonary artery pressure (PAP) of the patients who used once daily doses of sibutramine.